Key Takeaways
- Emalex Biosciences’ ecopipam significantly reduced relapse rates in children with Tourette syndrome during a phase 3 trial.
- The company plans to submit ecopipam for regulatory approval in 2025, following encouraging study results.
- Ecopipam’s most common side effects included drowsiness and insomnia, with an overall favorable efficacy profile compared to placebo.
Trial Results Show Promise for Ecopipam
Emalex Biosciences has reported encouraging results from a phase 3 clinical trial of ecopipam, a dopamine blocker aimed at treating Tourette syndrome. The trial comprised 216 participants, including 167 children and 49 adults, and was designed to evaluate the drug’s effectiveness in reducing both vocal and motor tics—a hallmark of the condition.
Participants first underwent a 12-week open-label period during which they received ecopipam. Following this, those who showed significant improvement were randomly assigned to either continue with ecopipam or switch to a placebo for an additional 12 weeks, a phase characterized by double-blind conditions. Results indicated that 41.9% of pediatric patients continued to experience tic reduction when maintained on ecopipam, significantly better than the 68.1% relapse rate observed in the placebo group. This primary endpoint highlighted the drug’s potential in managing Tourette syndrome symptoms effectively.
Emalex plans to file for FDA approval for ecopipam later in 2025. During the study, common side effects included drowsiness (10% of patients), insomnia (7%), anxiety, fatigue, and headaches. Despite these effects, the overall responses were favorable, leading the company’s chief medical officer, Frederick Munschauer, M.D., to express confidence in ecopipam as a potential first-in-class treatment.
The study’s secondary analysis, which combined results from both children and adults, revealed a similar relapse rate of 41.2% on ecopipam versus 67.9% on placebo. These findings build upon phase 2 results from earlier research, where ecopipam demonstrated a 30% reduction in tic severity in a group of young patients.
Ecopipam works by blocking the D1 dopamine receptor, which is believed to play a role in the compulsive behaviors associated with Tourette syndrome. This approach differs from existing therapies that primarily target the D2 receptor, potentially offering a novel treatment path for patients.
The progression of ecopipam has been supported financially, with Emalex successfully raising $250 million in a series D funding round in 2022, a significant increase from the $35 million series C raised previously. The firm was founded in 2018, backed by the biotech incubator Paragon Biosciences.
In a broader context, the field is seeing advancements in Tourette syndrome therapies. Recently, Noema Pharma reported positive results from its phase 2 trial of gemlapodect, a PDE10A inhibitor originally developed by Roche, which also showed potential in reducing tic severity among patients.
As Emalex finalizes plans for regulatory submission, the results from this trial offer hope for many individuals affected by Tourette syndrome, highlighting ecopipam’s potential to become a viable option in the treatment landscape.
The content above is a summary. For more details, see the source article.